VLS Valneva SE

VALNEVA Declaration of shares and voting rights - February 29, 2024

VALNEVA Declaration of shares and voting rights - February 29, 2024



 

VALNEVA

Declaration of shares and voting rights

February 29, 2024

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: March 6, 2024

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 



138,912,142



ordinary shares with a par value of €0.15 each
160,870,300  Double voting rights granted on 3,843 ordinary shares









 Transfer into bearer form of 1,000,000 shares with double voting rights
Between February 1 & February 25, 2024













  February 13, 2024
160,745,978

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.



 

Attachment



EN
06/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva annonce sa participation à des conférences investisseurs

Valneva annonce sa participation à des conférences investisseurs  Lyon (France), le 2 mars 2026 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et participeront à des rendez-vous avec des investisseurs institutionnels lors de prochaines conférences aux États-Unis et en Europe. Thomas Lingelbach, directeur général, et Peter Bühler, directeur financier, feront un point sur les principaux éléments de création de valeur de la Société ainsi que les catalyseurs attendus, dont les...

 PRESS RELEASE

Valneva to Participate in Upcoming Investor Conferences

Valneva to Participate in Upcoming Investor Conferences Lyon (France), March 2, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Buhler will discuss the Company’s key value drivers and upcoming catalysts, including the topline Phase 3 data readout for VLA15, the Company’s Lyme disease vaccine candidate, which partner Pfizer expects to report in the first half of 2026. The TD Cowen presenta...

Martial Descoutures
  • Martial Descoutures

ResearchPool Subscriptions

Get the most out of your insights

Get in touch